Literature DB >> 11186132

Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance.

K J Aitchison1, F J Gonzalez, L C Quattrochi, A Sapone, J H Zhao, H Zaher, G Elizondo, C Bryant, J Munro, D A Collier, A I Makoffa, R W Kerwin.   

Abstract

CYP1A2 activity has been demonstrated to be bimodally or trimodally distributed in several populations, consistent with a codominant or recessive functional genetic polymorphism. However, studies aimed at identifying polymorphisms in CYPIA2 have not yet adequately accounted for this distribution pattern. To search for functional polymorphisms, we performed genome-walking, polymerase chain reaction (PCR) sequencing, and cloning, and identified three novel polymorphisms in the 5' flanking region of CYP1A2: a T-3591G substitution, a G-3595T substitution, and a T-3605 insertion. The frequency of the T-3591G substitution was determined by a PCR-restriction fragment length polymorphism assay, and found to be significantly higher (P < 0.0001) in Taiwanese (allele frequency 0.128, n = 125) compared to Caucasians (0.017, n = 87) or African Americans (0.024, n = 104). The functional consequence of the T-3591G and the G-3595T substitutions was determined by site-directed mutagenesis followed by transient transfection experiments. The T-3591G mutation was shown to be nonfunctional, while although the G-3595T mutation appeared to result in an increase in promoter activity, this was only to a small degree and therefore unlikely to be important in vivo. In addition, we report 532 bases of 5' flanking sequence further upstream than that reported to date, and four sequence discrepancies compared to the original published sequence (G-3649C, deltaT-3650, deltaA-4072, and C-4093 ins).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11186132     DOI: 10.1097/00008571-200011000-00004

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  13 in total

1.  The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women.

Authors:  Anna Nordmark; Stefan Lundgren; Birgitta Ask; Fredrik Granath; Anders Rane
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 2.  Pharmacogenetics and psychiatry.

Authors:  Amlan Basu; Eva Tsapakis; Kathy Aitchison
Journal:  Curr Psychiatry Rep       Date:  2004-04       Impact factor: 5.285

Review 3.  Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing.

Authors:  Carsten Skarke; Anja Kirchhof; Gerd Geisslinger; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

4.  Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.

Authors:  Donghui Li; Li Jiao; Yanan Li; Mark A Doll; David W Hein; Melissa L Bondy; Douglas B Evans; Robert A Wolff; Renato Lenzi; Peter W Pisters; James L Abbruzzese; Manal M Hassan
Journal:  Carcinogenesis       Date:  2005-06-29       Impact factor: 4.944

5.  Bisphosphonates improve trabecular bone mass and normalize cortical thickness in ovariectomized, osteoblast connexin43 deficient mice.

Authors:  Marcus P Watkins; Jin Yi Norris; Susan K Grimston; Xiaowen Zhang; Roger J Phipps; Frank H Ebetino; Roberto Civitelli
Journal:  Bone       Date:  2012-06-29       Impact factor: 4.398

Review 6.  Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.

Authors:  Shu-Feng Zhou; Li-Ping Yang; Zhi-Wei Zhou; Ya-He Liu; Eli Chan
Journal:  AAPS J       Date:  2009-07-10       Impact factor: 4.009

7.  Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.

Authors:  Christoph Sachse; Upinder Bhambra; Gillian Smith; Tracy J Lightfoot; Jennifer H Barrett; Jenna Scollay; R Colin Garner; Alan R Boobis; C Roland Wolf; Nigel J Gooderham
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

8.  Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?

Authors:  Maju M Koola; Evangelia M Tsapakis; Padraig Wright; Shubulade Smith; Robert W Kerwin Rip; Katie L Nugent; Katherine J Aitchison
Journal:  J Psychopharmacol       Date:  2014-03-04       Impact factor: 4.153

9.  DNA sequence variation in a 3.7-kb noncoding sequence 5' of the CYP1A2 gene: implications for human population history and natural selection.

Authors:  S P Wooding; W S Watkins; M J Bamshad; D M Dunn; R B Weiss; L B Jorde
Journal:  Am J Hum Genet       Date:  2002-08-09       Impact factor: 11.025

10.  Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.

Authors:  Murielle Bochud; Michel Burnier; Idris Guessous
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.